Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2.Retention Bonus Agreement • February 27th, 2017 • Horizon Pharma PLC • Pharmaceutical preparations
Contract Type FiledFebruary 27th, 2017 Company IndustryAs you are aware, on September 12, 2016, Raptor Pharmaceutical Corp. (the “Company”) entered into a definitive agreement to be acquired by Horizon Pharma plc. (“Parent”). We expect the acquisition to close by the end of October of this year (the date the acquisition closes, the “Closing”).
EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND DAVID A. HAPPELExecutive Employment Agreement • February 27th, 2017 • Horizon Pharma PLC • Pharmaceutical preparations • Illinois
Contract Type FiledFebruary 27th, 2017 Company Industry JurisdictionThis Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045 (hereinafter referred to together as the “Company”) and David A. Happel (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing October 25, 2016 (the “Effective Date”).
AMENDMENTManufacturing and Supply Agreement • February 27th, 2017 • Horizon Pharma PLC • Pharmaceutical preparations
Contract Type FiledFebruary 27th, 2017 Company IndustryTHIS AMENDMENT (“Amendment”) is entered into effective this first day of January 2017, (“Effective Date”) by and between Jagotec AG (“Skyepharma”) and Horizon Pharma Ireland Limited (“Horizon”).
AMENDMENT NO. 1 TO SALES CONTRACTSales Contract • February 27th, 2017 • Horizon Pharma PLC • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 27th, 2017 Company Industry JurisdictionThis AMENDMENT NO. 1 (“Amendment”) is to that certain Sales Contract, dated as of July 1, 2010 (“Contract”), by and between Horizon Pharma USA, Inc. (“Buyer”) and BASF Corporation (“BASF” or “Seller”). Capitalized terms used and not defined herein shall have the respective meanings assigned to such terms in the Contract. This Amendment shall be effective as of January 1, 2016 (the “Amendment Effective Date”).